Related Experiment Video
Updated: Jun 29, 2026
07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
Programmed acute electrical stimulation of ventral tegmental area alleviates depressive-like behavior
Alexander Friedman1, Michael Frankel, Yakov Flaumenhaft
1Leslie and Susan Gonda (Goldschmied) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan, Israel.
Summary
Deep brain stimulation of the ventral tegmental area (VTA) offers a novel therapeutic approach for depression. This method shows faster and more effective alleviation of depressive behaviors compared to traditional antidepressants.
Area of Science:
- Neuroscience
- Psychiatry
- Neurobiology
Background:
- Depressive disorders impact ~5% of the population annually, with current treatments like antidepressants requiring weeks for efficacy.
- There is a critical need for novel therapeutic strategies to enhance treatment effectiveness and patient responsiveness in depression.
- Exploring alternative interventions beyond conventional pharmacotherapy is essential for advancing depression treatment.
Purpose of the Study:
- To investigate deep brain stimulation (DBS) of the ventral tegmental area (VTA) as an intervention for depressive states.
- To compare the efficacy of VTA DBS against chemical antidepressants and electroconvulsive therapy (ECT).
- To assess the impact of VTA DBS on behavioral manifestations of depression and neurobiological markers.
Main Methods:
- Programmed acute electrical stimulation of the VTA, mimicking normal rat VTA neuron firing patterns.
- Weekly monitoring of behavioral manifestations of depression using a battery of validated behavioral tests.
- Measurement of brain-derived neurotrophic factor (BDNF) mRNA levels in the prefrontal cortex.
Main Results:
- VTA deep brain stimulation significantly alleviated depressive behaviors in rats.
- The onset and longitudinal effects of VTA DBS were superior to those of chemical antidepressants and ECT.
- VTA DBS treatment correlated with increased BDNF mRNA levels in the prefrontal cortex.
Conclusions:
- Programmed acute electrical stimulation of the VTA is a promising novel intervention for depressive disorders.
- VTA DBS demonstrates faster onset and sustained efficacy in alleviating depressive behaviors compared to existing treatments.
- The therapeutic effects of VTA DBS may be linked to increased neurotrophic factor expression in key brain regions.
Related Concept Videos
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...